Kaye Randall

Executive Vice President & CMOLongboard Pharmaceuticals, Inc. (LBPH) · full profile →Form 4 · filed Dec 2, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
1 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 2, 2024Tender(U)31K$60.00$1.8M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 2, 2024Disposed to issuer(D)108K0
Dec 2, 2024Disposed to issuer(D)96K0
Dec 2, 2024Disposed to issuer(D)176K0
Dec 2, 2024Disposed to issuer(D)18K0
Dec 2, 2024Disposed to issuer(D)10K0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-028023) within minutes of acceptance. Every field above traces to the original document. Verify it directly: